tt-00973
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2023 (NCT05673538)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
FLT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05673538 | Phase 1 | Jan 31, 2023 | Central South University, TransThera Biosciences Co., Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| TransThera Biosciences Co., Ltd | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1